BIB vs. LABU
Compare and contrast key facts about ProShares Ultra Nasdaq Biotechnology (BIB) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).
BIB and LABU are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. BIB is a passively managed fund by ProShares that tracks the performance of the NASDAQ Biotechnology Index (200%). It was launched on Apr 7, 2010. LABU is a passively managed fund by Direxion that tracks the performance of the S&P Biotechnology Select Industry Index (300%). It was launched on May 28, 2015. Both BIB and LABU are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BIB or LABU.
Key characteristics
| BIB | LABU | |
|---|---|---|
| YTD Return | -13.86% | -27.08% |
| 1Y Return | -15.21% | -25.59% |
| 3Y Return (Ann) | -17.98% | -61.07% |
| 5Y Return (Ann) | 0.01% | -38.35% |
| Sharpe Ratio | -0.40 | -0.25 |
| Daily Std Dev | 33.03% | 83.46% |
| Max Drawdown | -67.24% | -98.92% |
| Current Drawdown | -55.87% | -98.06% |
Correlation
The correlation between BIB and LABU is 0.92, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Performance
BIB vs. LABU - Performance Comparison
In the year-to-date period, BIB achieves a -13.86% return, which is significantly higher than LABU's -27.08% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
BIB vs. LABU - Expense Ratio Comparison
BIB has a 0.95% expense ratio, which is lower than LABU's 1.12% expense ratio.
Risk-Adjusted Performance
BIB vs. LABU - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
BIB vs. LABU - Dividend Comparison
BIB's dividend yield for the trailing twelve months is around 0.16%, less than LABU's 0.66% yield.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 0.16% | 0.07% | 0.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LABU Direxion Daily S&P Biotech Bull 3x Shares | 0.66% | 0.35% | 0.00% | 0.00% | 0.00% | 0.28% | 0.64% | 0.17% |
Drawdowns
BIB vs. LABU - Drawdown Comparison
The maximum BIB drawdown since its inception was -67.24%, smaller than the maximum LABU drawdown of -98.92%. Use the drawdown chart below to compare losses from any high point for BIB and LABU. For additional features, visit the drawdowns tool.
Volatility
BIB vs. LABU - Volatility Comparison
The current volatility for ProShares Ultra Nasdaq Biotechnology (BIB) is 9.38%, while Direxion Daily S&P Biotech Bull 3x Shares (LABU) has a volatility of 21.67%. This indicates that BIB experiences smaller price fluctuations and is considered to be less risky than LABU based on this measure. The chart below showcases a comparison of their rolling one-month volatility.